Objective: To evaluate the effect of neoadjuvant chemotherapy in the treatment of locally advanced breast cancer.
前言： 目的：探讨新辅助化疗在局部晚期乳腺癌治疗中的应用。
Methods: 32 patients with locally advanced breast cancer treated by neoadjuvant chemotherapy were reviewed retrospectively.
方法：回顾性分析32例局部晚期乳腺癌患者进行新辅助化疗的临床资料。
Conclusion Neo-adjuvant chemotherapy with ET regimen for 4 cycles were more effective than 2 cycles to down staging locally advanced breast cancer.
结论ET方案对局部进展期乳腺癌进行新辅助化疗，在肿瘤及淋巴结缩小（降期）效果方面，4周期组明显优于2周期组。
The neoadjuvant chemotherapy and regular endocrine therapy are the necessary measures to improve the survival rates of locally advanced breast cancer.
术前辅以新辅助化疗，术后辅以正规内分泌治疗是提高局部晚期乳腺癌生存率的必要手段。
Therefore, improving the earlier diagnosis to give the earlier treatment is the key point to improve the survival rates of locally advanced breast cancer.
因此努力提高局部晚期乳腺癌的早诊断，做到早治疗是提高局部晚期乳腺癌生存率的关键。
Objective to evaluate the clinical efficacy and toxicity of CEF as the neoadjuvant chemotherapy regimen in the treatment of locally advanced breast cancer (LABC).
目的评价CEF方案新辅助化疗治疗局部晚期乳腺癌的临床疗效和毒性反应。
All 305 women in the study (median age 55 years) had locally advanced or metastatic breast cancer, and all had been treated with an anthracycline.
入组的所有305名女性(中位年龄55岁)当中要么已是乳癌晚期患者，要么是乳癌转移患者，而且都接受了蒽环类药物的治疗。
All 305 women in the study (median age 55 years) had locally advanced or metastatic breast cancer, and all had been treated with an anthracycline.
入组的所有305名女性(中位年龄55岁)当中要么已是乳癌晚期患者，要么是乳癌转移患者，而且都接受了蒽环类药物的治疗。
应用推荐